ITeos Therapeutics Company

ITeos Therapeutics is a private biotechnology company targeting the metabolism of the tumor microenvironment to develop small molecule immunomodulators for cancer treatments. iTeos is building its activities upon the unparalleled expertise of the Ludwig Cancer Research (LICR) – a world-class Research Institute in the fields of tumor immunology, therapeutic cancer vaccines, cancer biology, and translational medicine in cancer. iTeos endeavors to develop small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints (e.g. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies).
Technology: Biotechnology, Health Care, Medical
Industry: End-to-end Drug Development
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 2011-01-01
Employees Number: 11-50
Funding Status: IPO
Investors Number: 17
Total Funding: 249739241
Estimated Revenue: $1M to $10M
Last Funding Date: 2020-04-01
Last Funding Type: Series B

Visit Website
Register and Claim Ownership